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Background: Metabolic syndrome is associated with cardiovascular diseases and is characterized by insulin resis-
tance. Recent studies suggest that the triglyceride/high-density lipoprotein cholesterol (TG/HDLC) ratio predicts 
insulin resistance better than individual lipid levels, including TG, total cholesterol, low-density lipoprotein choles-
terol (LDLC), or HDLC. We aimed to elucidate the relationship between the TG/HDLC ratio and metabolic syn-
drome in the general Korean population.
Methods: We evaluated the data of adults ≥20 years old who were enrolled in the Korean National Health and Nu-
trition Examination Survey in 2013 and 2014. Subjects with angina pectoris, myocardial infarction, stroke, or cancer 
were excluded. Metabolic syndrome was defined by the harmonized definition. We examined the odds ratios (ORs) 
of metabolic syndrome according to TG/HDLC ratio quartiles using logistic regression analysis (SAS ver. 9.4; SAS 
Institute Inc., Cary, NC, USA). Weighted complex sample analysis was also conducted.
Results: We found a significant association between the TG/HDLC ratio and metabolic syndrome. The cutoff value 
of the TG/HDLC ratio for the fourth quartile was ≥3.52. After adjustment, the OR for metabolic syndrome in the 
fourth quartile compared with that of the first quartile was 29.65 in men and 20.60 in women (P<0.001).
Conclusion: The TG/HDLC ratio is significantly associated with metabolic syndrome.
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INTRODUCTION
Cardiovascular diseases occur more frequently in patients with meta-
bolic syndrome.1) In particular, in middle-aged men with metabolic 
syndrome the risk of total mortality due to cardiovascular diseases is 
2.6–3.0 times higher than observed in individuals without metabolic 
syndrome.2) Insulin resistance is important in metabolic syndrome 
and is associated with many diseases including coronary disease, hy-
pertension, adult-onset diabetes, obesity, and stroke.3-6)
 Dyslipidemia is also a risk factor for cardiovascular diseases. Con-
ventionally, the role of triglycerides (TGs), high-density lipoprotein 
cholesterol (HDLC), and low-density lipoprotein cholesterol (LDLC) 
have been emphasized. High TG and low HDLC are independent risk 
factors of cardiovascular diseases.7,8) TGs and HDLC are also compo-
nents of metabolic syndrome. In practice, many clinicians focus pri-
marily on LDLC in high-risk cardiovascular patients. However, 60% to 
70% of cardiovascular events occur despite therapy to lower LDLC lev-
els.9) Also, a prior study reported that high LDLC levels do not increase 
the risk of mortality in women.10)
 Recently, the TG/HDLC ratio was suggested as a compliment to 
LDLC for predicting the risk of cardiovascular diseases. The TG/HDLC 
ratio is significantly related to insulin resistance11-13) and also appears 
to be useful in predicting the development of diabetes,14) coronary 
heart disease, and cardiovascular mortality.15) Previous studies have 
demonstrated that the TG/HDLC ratio is a better screening index for 
insulin resistance than the homeostasis model assessment for insulin 
resistance.16)
 It would be clinically useful to identify insulin-resistant individuals 
before the appearance of cardiovascular diseases. One method has 
been to assess the number of criteria for metabolic syndrome present 
in a patient.17) Several studies have suggested that the TG/HDLC ratio 
can identify insulin-resistant individuals in a simpler manner.11-13) Also, 
the TG/HDLC ratio has been shown to be comparable to of the use of 
metabolic syndrome criteria in identifying insulin resistance in appar-
ently healthy individuals.18,19)
 Data on the association between the TG/HDLC ratio and metabolic 
syndrome in the Korean population is limited. If the TG/HDLC ratio 
could be shown to be closely associated to metabolic syndrome, mea-
surement of the TG/HDLC ratio may be clinically useful because of its 
simplicity. Determination of the TG/HDLC ratio does not require a 
measurement of waist circumference, a measurement that varies with 
sex and ethnicity and is not routinely checked in clinical situations. We 
aimed to elucidate the relationship between the TG/HDLC ratio and 
metabolic syndrome in the general Korean population.
METHODS
We evaluated the original data of adults aged ≥20 years who were en-
rolled in the Korean National Health and Nutrition Examination Sur-
vey in 2013 and 2014. Subjects with a history of angina pectoris, myo-
cardial infarction, stroke, or cancer were excluded from the study. The 
metabolic syndrome definition was based on the harmonized defini-
tion emphasizing variations of waist circumference according to racial 
groups.17) Metabolic syndrome was defined by fulfilling ≥3 compo-
nents. For central obesity, the definition of the Korean Society for The 
Study of Obesity was used.20) Because most drugs for the treatment of 
dyslipidemia (statins) primarily target the lowering of LDLC, the use of 
medication for dyslipidemia was ignored.
 The following were the components used to assess for the presence 
of metabolic syndrome: (1) waist circumference >90 cm (men), >85 
cm (women); (2) hypertriglycemia TG ≥150 mg/dL; (3) HDLC <40 mg/
dL (men), <50 mg/dL (women); (4) hypertension: systolic blood pres-
sure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or on antihy-
pertensive medication; and (5) fasting glucose ≥100 mg/dL or on 
medication for hyperglycemia.
1. Statistical Analysis
The original data from the 2013 and 2014 Korean National Health and 
Nutrition Examination were merged. Only the data of significant fig-
ures needed for analysis were used. Age (categorization), smoking sta-
tus, drinking status, daytime physical activity, numbers of components 
of metabolic syndrome, metabolic syndrome status, quartiles for the 
TG/HDLC ratio, and LDLC, a chi-square test and t-test were conduct-
ed. The LDLC level was calculated using Friedewald’s equation 
(LDLC=TC-HDLC-TG/5). The relationship between the number of 
metabolic syndrome components and the TG/HDLC ratio was ana-
lyzed by multiple regression, and the odds ratio (OR) of metabolic syn-
drome according to the TG/HDLC ratio was analyzed by logistic re-
gression. Weighted complex sample analysis was conducted. All anal-
yses were performed using SAS ver. 9.4 (SAS Institute Inc., Cary, NC, 
USA). 
RESULTS
1. General Characteristics of the Study Population
From the total 32,875,039 selected adults (16,375,805 men [49.81%] 
and 16,499,234 women [50.19%]), 4,200,892 men (25.65%) and 
2,956,022 women (17.92%) met the criteria of metabolic syndrome. In 
both men and women, metabolic syndrome was significantly associ-
ated with age, drinking, exercise, blood pressure, waist circumference, 
white blood cell count, fasting glucose, and lipid profile (Table 1). In 
men, the TG/HDLC ratio was 2.73±0.05 in those without metabolic 
syndrome and 6.80±0.20 in those with metabolic syndrome, a statisti-
cally significant difference (P<0.001). In women, the TG/HDLC ratio 
was 1.73±0.03 in those without metabolic syndrome and 4.65±0.11 in 
those with metabolic syndrome, also a statistically significant differ-
ence (P<0.001).
2. The Relationship between the Triglyceride/High-Density 
Lipoprotein Cholesterol Ratio and the Number of 
Components of Metabolic Syndrome
The mean value of the TG/HDLC ratio increased as the number of 
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metabolic syndrome components increased: 1.61 with no compo-
nents; 2.71 with 1 component; 4.20 with 2 components; 6.17 with 3 
components; 7.33 with 4 components; and 10.92 with 5 components 
in men. In women, the mean TG/HDLC ratio was 1.17 with no com-
ponents; 1.78 with 1 component; 2.92 with 2 components; 3.98 with 3 
components; 5.39 with 4 components; and 6.34 with 5 components. 
The ratio increased significantly with the increase in the number of 
components present (P<0.001) (Table 2).
3. The Odds Ratios for Metabolic Syndrome according to 
the Triglyceride/High-Density Lipoprotein Cholesterol 
Ratio
The TG/HDLC ratio was divided by quartile. After adjustment, the OR 
for metabolic syndrome in the fourth quartile compared with that of 
the first quartile was 29.65 in men and 20.60 in women (P<0.001) (Ta-
ble 3).
DISCUSSION
In this study, we aimed to elucidate the relationship between the TG/
HDLC ratio and the presence of metabolic syndrome characterized by 
insulin resistance. The TG/HDLC ratio accordingly increased signifi-
cantly in both men and women with an increase in the number of 
metabolic syndrome components present. In a previous study that in-
vestigated the relationship between the TG/HDLC ratio and metabolic 
syndrome in Koreans visiting a health-screening center, the cutoff val-
ue of the TG/HDLC ratio in the fourth quartile of was ≥2.93.21) In pres-
ent study, the fourth quartile was 3.52. The OR for metabolic syndrome 
was 29.65 in men and 20.60 in women.
 Metabolic syndrome is characterized by insulin resistance and is 
primarily caused by central obesity. A recent meta-analysis showed 
that the total mortality rate was lower in overweight people as defined 
by body mass index (BMI).22) In adult males, central obesity with nor-
mal weight defined by BMI was twice as high as the total mortality of 
being overweight or obese by BMI without central obesity.23) Central 
obesity and insulin resistance are important components of the meta-
bolic syndrome.
 The finding that the TG/HDLC ratio is significantly related to meta-
bolic syndrome can be explained based on multiple mechanisms. 
First, the TG/HDLC ratio predicts insulin resistance.11-13) Insulin resis-
tance promotes the accumulation of fat in the body, resulting in obesi-
ty. Insulin resistance also facilitates the progression to pre-diabetes or 
diabetes, and is associated with hypertension. Moreover, insulin resis-
tance induces endothelial dysfunction of the blood vessels and is as-
sociated with oxidant stress and hormone and cytokine secretion from 
fat cells, resulting in inflammation that promotes the development of 
atherosclerosis.
 Second, the TG/HDLC ratio is known to predict the level of detri-
mental LDLC subtypes including type B LDLC.24,25) There are several 
sub-types of LDLC, and types A and B have received the greatest atten-
tion. Type A LDLC is large in volume and is not considered to be 
harmful. However, the smaller and denser type B LDLC is easily oxi-
dized and triggers inflammation and atherosclerosis, resulting in arte-
rial stiffness.26,27) The TG/HDLC ratio is independently associated with 
Table 3. Odds ratios for metabolic syndrome across the TG/HDLC ratio quartiles
Quartile of TG/
HDLC ratio 
(ratio value)
Odds ratio for male Odds ratio for female
Unadjusted (95% CL) P-value Adjusted† (95% CL) P-value Unadjusted (95% CL) P-value Adjusted† (95% CL) P-value
Q1 (<1.28) 1 1 1 1
Q2 (1.28–2.12) 2.76* (1.23–6.19) 0.0138 1.67 (0.54–5.17) 0.3734 1.45 (0.88–2.37) 0.1458 0.70 (0.39–1.28) 0.2451
Q3 (2.12–3.52) 7.11*** (3.39–14.92) <0.0001 4.13** (1.44–11.87) 0.0084 4.75*** (2.80–8.06) <0.0001 2.23** (2.02–6.16) 0.0063
Q4 (≥3.52) 28.38*** (13.23–60.90) <0.0001 29.65*** (10.53–83.53) <0.0001 16.20*** (7.63–34.41) <0.0001 20.60*** (11.33–37.44) <0.0001
TG, triglyceride; HDLC, high-density lipoprotein cholesterol; CL, confidence level.
*P<0.05. **P<0.01. ***P<0.001. †Adjusted for age, smoking status, alcohol history, waist circumference, HDLC, low-density lipoprotein cholesterol, blood pressure, fasting 
glucose, and white blood cell count.
Table 2. TG/HDLC ratio according to the number of metabolic components present
No. of components
Male Female
No. (%) TG/HDLC ratio (95% CL for mean) No. (%) TG/HDLC ratio (95% CL for mean)
0 4,559,816 (27.85) 1.61±0.03 (1.56–1.66) 6,553,087 (39.72) 1.17±0.01 (1.15–1.20)
1 4,044,732 (24.70) 2.71±0.07 (2.58–2.85) 4,165,070 (25.24) 1.78±0.03 (1.73–1.83)
2 3,570,365 (21.80) 4.20±0.13 (3.94–4.45) 2,825,055 (17.12) 2.92±0.10 (2.72–3.12)
3 2,701,419 (16.50) 6.17±0.25 (5.67–6.67) 1,744,092 (10.57) 3.98±0.13 (3.73–4.23)
4 1,247,920 (7.62) 7.33±0.34 (6.66–7.99) 924,586 (5.60) 5.39±0.20 (5.00–5.79)
5 251,553 (1.54) 10.92±1.16 (8.64–13.21) 287,343 (1.74) 6.34±0.36 (5.64–7.04)
P-trend <0.001 <0.001
P-values were calculated using simple regression analysis.
TG, triglyceride; HDLC, high-density lipoprotein cholesterol; CL, confidence level.
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an increase in arterial stiffness in healthy individuals.28)
 A strength of this study is that the results are reliable in terms of gen-
eral applicability to the Korean population. A weakness of this cross-
sectional study is the lack of clinical outcomes, we cannot conclude 
that the TG/HDLC ratio is as powerful in predicting clinical outcomes 
as is the metabolic syndrome. Further studies are needed to determine 
which factors, including the TG/HDLC ratio, best predict the morbidi-
ty and mortality rate of cardiovascular diseases in patients with the 
metabolic syndrome. Because lipid profiles vary with nationality, gen-
der, and ethnicity, additional studies are needed to determine the ap-
propriate cutoff points of the TG/HDLC ratio among these different 
populations.
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